Here is a number that should stop you cold: $807 million.

That is Axon Enterprise's Q1 2026 revenue — up 34% year-over-year. The company raised its full-year revenue outlook, analysts are scrambling to lift targets, and Zacks just upgraded the stock to Strong Buy.

And the stock is down roughly 30% year-to-date.

Let that sink in for a moment. A company growing revenue at 34% — not from a pandemic bounce, not from a one-time contract, but from sustainable, government-backed recurring revenue — is being sold off alongside the rest of the defense and tech sector as if its business model broke.

It didn't. The market's collective freak-out over defense sector headwinds, tariff noise, and rotation out of high-multiple growth names has created what looks increasingly like a classic signal-versus-noise disconnect.

▶ CNBC Television
Axon CEO Rick Smith goes one-on-one with Jim Cramer

The Numbers Don't Lie — The Market Is Just Confused

Let's be precise about what Axon delivered in Q1 2026:

  • Revenue: $807M, up 34% YoY — well above consensus expectations.
  • Annual Recurring Revenue (ARR): Crossed $1.5B, up 35% YoY.
  • Net Revenue Retention (NRR): 125% — meaning existing customers expand their spend by a quarter every single year.
  • Full-year guidance: Raised, signaling management's confidence in accelerating demand.
  • Analyst consensus: Zacks upgraded to Strong Buy. Median price target sits at $662 — implying 71% upside from current levels near $386.

These are not the numbers of a company in trouble. These are the numbers of a company firing on all cylinders. The sell-off is entirely a function of macro rotation — not fundamentals.

The Contrarian Math Is Compelling

At $386, Axon trades at roughly 36x forward earnings. For a 34% revenue grower with 125% NRR and a government-backed revenue base that is effectively recession-proof, that multiple is not expensive — it's reasonable verging on cheap.

Consider the asymmetry: the Wall Street analyst community sees $662 as the median target. At the high end, estimates reach $825 — more than double the current price. Even the lowest analyst target sits at $409.68, above where the stock trades today.

That means every single analyst covering the stock sees upside. The debate is not if AXON goes higher, but how much.

Why This Sell-Off Is Different

The defense and tech sectors have been under intense selling pressure in 2026 as geopolitical uncertainty, shifting trade policy, and a broad rotation out of growth names have punished even the strongest operators. Axon was caught in the blast radius despite having no exposure to the factors driving the sell-off.

Police departments do not cancel body camera contracts because of tariffs. Municipalities do not pause Taser orders because of Fed policy. Federal law enforcement agencies do not scale back evidence management software subscriptions because of sector rotations.

Axon's revenue base is stickier than almost any company in the market. Its customers cannot switch providers. Its products are embedded in the daily operations of thousands of law enforcement agencies. And its AI-powered tools — Draft One for automated report writing, Evidence.com for digital evidence management — are becoming as essential as the body cameras themselves.

The AI Growth Engine Nobody Is Pricing In

Axon's AI software revenue exploded in Q1 2026. The company's Draft One product — which uses AI to generate incident reports from body camera footage — is seeing adoption rates that suggest it could become a multi-hundred-million-dollar revenue stream on its own. Axon's cloud software and AI services now represent an increasingly large share of the revenue mix, driving higher margins and deeper customer lock-in.

The market is still pricing Axon as a hardware company that sells Tasers. The reality is that Axon is a software platform with a hardware distribution channel. That mispricing is the arbitrage.

The Bottom Line

When a 34% revenue grower with a $662 analyst target drops 30% YTD for reasons entirely unrelated to its business, the market is offering you a gift. It may take time for sentiment to catch up to reality — macro rotations can persist longer than fundamentals justify — but the gap between Axon's intrinsic trajectory and its current stock price is as wide as it has been all year.

This is not a turnaround story. It is a compounder on sale. Axon is executing at the highest level in its history, and the market is too distracted by the noise to notice.

Your move.